TetraQ is a preclinical drug development facility located at the University of Queensland in Brisbane, Australia. It was founded in 2005 by four experts in the core areas of preclinical drug development - efficacy, ADME, toxicology, and pharmaceutics. TetraQ provides a range of preclinical services including efficacy testing in disease models, ADME/pharmacokinetic studies, toxicology testing, and formulation development to assess drug candidates and help reduce risks prior to clinical trials. The services help determine whether drug candidates are likely to be safe and effective enough to advance to human studies.

1. Where is TetraQ?
 Located at The University of Queensland in Brisbane
Brisbane (UQ), Queensland
 Joint initiative of UQ, Queensland Institute for
Medical Research (QIMR) and Q-Pharm
 Part funded by the Queensland Government Smart
State Research Facilities Fund
 8.1 M$ invested in State-of-the-art infrastructure
 GLP recognized
 Staffing – 30 FTE + casuals
Quality Preclinical Drug Development Solutions

2. Who founded TetraQ?
4 Founders
Professors Ron Dickinson, Istvan Toth, Rod
Minchin & Maree Smith
 Internationally recognized experts in the four
core preclinical disciplines –
• ADME
• Efficacy
• Toxicology
• Pharmaceutics
 100 yrs expertise & know-how amongst
founders
 60 yrs of commercialization experience
amongst founders
Quality Preclinical Drug Development Solutions

3. How is TetraQ structured?
Centre for Integrated Preclinical Drug Development (CIPDD)
Research Training The Hub of Organics
Analysis
Commercial arm of Targeted to bringing Short courses for
CIPDD; Business innovation into Drug Industry Bioanalysis Services
undertaking contract R&D Development “Toolkit” for UQ researchers
for biotech & Pharma i.e. methods research
clients Preclinical Seminars
Modern GLP facilities
Funded by research with the latest equipment
Registered business
grants: Govt + Industry Training of PhD students and highly trained
name of UniQuest - working on “toolkit technical staff for
contracting entity research” services to University of
QLD researchers
Quality Preclinical Drug Development Solutions

4. What is the significance of TetraQ services?
 Assess potential therapeutic effects of the drug candidate in living
organisms
 Gather sufficient data to determine reasonable safety of the drug
candidate in humans through laboratory experimentation and animal
studies
 Determine whether the drug candidate is ever likely to be developed as a
pharmaceutical
“Fail early, fail cheap”
Quality Preclinical Drug Development Solutions

5. Why is this significant?
 Expensive exercise – $US 800 – 1200 million
 Long timelines – 10-15 yrs
 Huge risk of failure
 Only 1 in 5000 molecules from drug discovery will make it to
market and become a new product
Quality Preclinical Drug Development Solutions

6. Where does TetraQ fit into the drug development phases?
Preclinical Phase I Phase II Phase III
Drug Discovery Drug Clinical Clinical Clinical
Development Trials Trails Trails
Quality Preclinical Drug Development Solutions

7. What are the services TetraQ provide?
Assessment of:
 Efficacy:
 “Does it work?”
 Cell-based assays and animal models of human disease
 ADME - Pharmacokinetics and metabolism:
 “How can it be delivered and what does the body do to it?”
 Absorption, distribution, metabolism, elimination (ADME)
 Toxicology:
 “Is it safe?”
 Cell-based assays and animal testing
 Pharmaceutics:
 “Is its manufacture viable and controllable?”
 Physicochemical properties; formulation studies, stability
Quality Preclinical Drug Development Solutions

8. Efficacy – Biological Services
Is the drug candidate effective against the target disease?
 Proof-of-concept studies in animal models of human disease
 Pain: nociceptive, inflammatory, neuropathic
 Arthritis
 CNS Models - Multiple sclerosis, Parkinson‟s disease
 Obesity
 Diabetes
Quality Preclinical Drug Development Solutions

9. Pharmaceutics
Does the drug candidate have the right physical, chemical & biological
properties to become a medicine for human use?
 Physicochemical characterization
 FTIR, UV,NMR,MS
 Solubility studies
 Stability trials & stability indicating method development
 Dissolution studies
Quality Preclinical Drug Development Solutions

10. Toxicology
TetraQ-Toxicology facilities are GLP recognised
Is the drug candidate sufficiently safe to administer to humans in early
stage clinical trials ?
 Genotoxicity assays (Ames Test, Micronucleus, Mouse Lymphoma Assay)
 In vivo acute & repeat dose (chronic) toxicity studies
 In vivo safety pharmacology (including hERG, respiratory and CNS)
 Cytotoxicity assessment
 In vivo – two species, rodent and non rodent (dog, primates)
Project Management Services
 Preclinical development plans
Quality Preclinical Drug Development Solutions

11. ADME – Bioanalytic Services
(absorption, distribution, metabolism elimination)
TetraQ-ADME is GLP recognised & has NATA ISO 17025, Research &
Development Accreditation
 World leaders in bioanalytical method development &
sample analysis of drugs/metabolites in biological fluids,
human and animal samples
 Validated bioanalytical methods
 HPLC, LC-MS/MS, ELISA
 Screening, partially validated, fully validated to satisfy
FDA requirements
 Bioavailability and pharmacokinetic studies
 Drug metabolism studies including metabolite identification
 Biodistribution and plasma protein binding studies
 Toxicokinetics
Quality Preclinical Drug Development Solutions

12. What Clinical trial experience does TetraQ have?
HAHA Assay
 Transferred and validated HAHA assay (Human antibody/human antibody) and
anaylsed 100‟s of samples
ELISA Assay (Only Australian laboratory ISO-17025 R&D accredited for ELISA)
 Transferred and conducted partial validation of ELISA assay for major Australian
biotech organisations with analysis of 1500 plasma samples
 LC-MS/MS - 3 synthetic peptides in a single vaccine
 Fully validated in rat plasma to FDA requirements
 Analysis of samples from Toxicokinetic study
Small molecules - LC-MS/MS
Bioequivalence studies for generics
Quality Preclinical Drug Development Solutions

13. Quality is Key!
 Our Quality System is maintained by a full-time Quality Assurance
Manager who is supported by trained QA staff in each facility
 TetraQ-ADME - NATA ISO 17025, Research & Development
Accreditation
 TetraQ-ADME and TetraQ-Toxicology are GLP recognised facilities
 Data acceptable for Australian and international regulatory
submission
Quality Preclinical Drug Development Solutions

14. Who are TetraQ clients?
 Australian biotech and pharma companies
 ASX-listed & private companies
 International clients
 Based in USA, Europe, Asia & Japan
 Universities, Research Institutes, Big Pharma
 300 projects for 70 clients since inception in May 2005
 Frequent repeat business
 Indicates strong client satisfaction
Quality Preclinical Drug Development Solutions

15. Why use TetraQ Services?
 TetraQ offer Tailored solutions, not just a menu of choices
 Four world class facilities with "State of the art” equipment including LC-
MS/MS, HPLC and ELISA equipment
 Highly skilled scientific and management team,
Services backed by a leadership team with wealth experience in all 4
areas of preclinical drug development
Quality science behind all services (no short cuts)
 Modern PC2, SPF central animal breeding facilities
 We assist clients with data interpretation to facilitate and guide timely
decision-making
 A „one-stop shop‟ for early stage drug development
Quality Preclinical Drug Development Solutions

16. Thank you for your interest in TetraQ
Dean Simonsen We are focused to provide
- Sales & Services Manager
- Mb: 61 409 480 532 preclinical drug development
solutions to meet your needs
- Email: d.simonsen@tetraq.com.au
- PH: 61 7 3346 9933
- Fx: 61 7 3346 7391
Please feel free to ask questions to
Rose-marie Pennisi
- Commercial Manager
better understand how we may
- Mb: 61 437 112 549
- Email: r.pennisi@tetraq.com.au assist your organisation
Quality Preclinical Drug Development Solutions